Follistatin Results Timeline: What Studies Measured, and When

What a "results timeline" can and cannot be built from

People searching for a follistatin timeline are usually looking for a week-by-week schedule of measurable change following administration of a compound. The published literature summarised here does not support that framing. The 2026 Sports Medicine review of the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance surveyed peptides promoted for performance and recovery and examined how much controlled human evidence sat behind each, alongside their regulatory status (PMID 41966639). Within the verified papers used on this page, no randomised human trial administered follistatin protein to volunteers and followed defined endpoints at set intervals.

What does exist is follistatin — and the closely named follistatin-like proteins — appearing as a measured variable inside studies about something else: exercise trials, disease biomarker panels, and cell-culture work. Those studies do have timepoints, and those timepoints are reportable. The distinction matters: a marker measured at week 12 of a training programme tells a reader when researchers sampled, not what a compound does on a schedule.

Where follistatin appears, and on what clock

The 12- and 16-week exercise windows

The clearest fixed timepoints come from sarcopenia exercise research, where follistatin sits inside broader panels of circulating muscle growth factors. A randomised controlled trial examined the effects of 16 weeks of resistance training on muscle quality and muscle growth factors in older adult women with sarcopenia, meaning its growth-factor sampling was anchored to a four-month training block rather than to any administered compound (PMID 34201810). A separate trial compared 12 weeks of whole-body vibration training against resistance training in older people with sarcopenia, giving a three-month observation window for its outcome measures (PMID 40011687).

A third randomised controlled trial compared low-load resistance training with blood flow restriction against conventional high-intensity resistance training in older people diagnosed with sarcopenia, using a pre-versus-post training design (PMID 39558011). Taken together, these three trials illustrate the practical convention in the field: muscle-related circulating factors are typically sampled at baseline and again at the end of a 12- to 16-week block, with few or no intermediate readings (PMID 34201810, PMID 40011687). That convention means the literature cannot say when within those months a marker first moved — only where it stood at the endpoint.

Why those trials are not follistatin trials

None of the three sarcopenia trials administered follistatin. Their interventions were resistance training, whole-body vibration and blood-flow-restricted training respectively, and the growth-factor measurements were secondary descriptions of the biological response to exercise in older adults with sarcopenia (PMID 34201810, PMID 39558011). Readers looking for a compound timeline should treat these as evidence about exercise, not about peptide administration.

Single-timepoint human profiling: no timeline at all

Several human studies measured components of the activin–follistatin system without any longitudinal schedule. Researchers profiled serum and pulmonary expression of the activin signalling system in pulmonary arterial hypertension, comparing expression patterns rather than tracking change over defined weeks (PMID 37096577). Another study examined the activin A/follistatin axis in airway diseases and its association with recurrent exacerbations, linking axis measurements to clinical event history rather than to a treatment calendar (PMID 40877175).

A transcriptomic analysis of shared deregulated neutrophil responses in COVID-19 and idiopathic pulmonary fibrosis worked from gene-expression datasets, which capture a molecular snapshot at the moment of sampling (PMID 40500689). Studies of this design can show that a signalling system differs between groups; the study design cannot show how quickly anything changes, because no repeated timepoints were built into it (PMID 37096577).

Follistatin-like proteins are a separate literature

Searches for follistatin frequently surface papers on FSTL1 and FSTL3. These are follistatin-like proteins — related by family name, studied in different contexts, and not interchangeable with follistatin itself. Researchers reported that FSTL3 functioned as a biomarker of poor prognosis and was associated with immunotherapy resistance in ovarian cancer (PMID 41029436). A separate study described FSTL3-driven cuproptosis resistance and endothelial progenitor cells in oral squamous cell carcinoma metastasis (PMID 41996175). In colon cancer, researchers reported that FSTL1 acted as a prognostic marker and promoted invasion and metastasis (PMID 41296128).

The "timeline" in these papers is survival and prognostic follow-up in patient cohorts and laboratory metastasis models, not a dosing schedule. They are cited here so readers can recognise that an FSTL3 oncology abstract is answering a different question from a muscle-physiology one (PMID 41029436, PMID 41296128).

In-vitro timescales: days in a dish, not weeks in a person

Cell-culture work involving the follistatin–activin system runs on a laboratory clock. Researchers derived granulosa-like cells from human endometrial induced pluripotent stem cells and assessed autologous estradiol production, a differentiation and functional-assay sequence carried out entirely in vitro (PMID 41236707). Results from such protocols describe what cells did under culture conditions; they do not translate into weeks-to-effect estimates for any person, and the study did not claim otherwise (PMID 41236707).

Context studies that discuss timing indirectly

A 2024 Endocrine Reviews article on Relative Energy Deficiency in Sport reviewed endocrine manifestations, pathophysiology and treatments in athletes, covering how endocrine systems respond in states of low energy availability (PMID 38488566). Reviews of this kind describe the direction and clinical framing of hormonal disturbance and its management, but a narrative review is not a source of measured timepoints for any individual marker, and the article was not designed as a follistatin kinetics study (PMID 38488566).

Follistatin Safety and Adverse Events: What Studies Report

The verified literature here contains no controlled human safety dataset for administered follistatin, and no adverse-event rates, dose ranges or discontinuation figures can be quoted without inventing them. The 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance addressed exactly this gap, assessing safety and efficacy across peptides that circulate in sport and performance settings, including those that have not been approved for such uses (PMID 41966639).

Indirect biological context exists in the disease literature. Researchers found the activin signalling system altered in pulmonary arterial hypertension serum and lung tissue (PMID 37096577), and reported the activin A/follistatin axis to be associated with recurrent exacerbations in airway disease (PMID 40877175). Oncology work reported follistatin-like proteins tracking with poor prognosis and metastatic behaviour (PMID 41029436, PMID 41296128). These findings describe a pathway embedded in immune, vascular and tumour biology; they are observational associations, not safety outcomes from administering anything.

What a genuine human timeline would require

Reading across the cited papers, the elements a results timeline would need are visible mainly by their absence:

• Repeated sampling. The sarcopenia trials reported endpoints anchored to 16-week and 12-week programmes, with change described across the block rather than at weekly intervals (PMID 34201810, PMID 40011687).
• A defined intervention. In those trials the intervention was exercise — resistance training, vibration training, or blood-flow-restricted low-load training — not a peptide (PMID 39558011).
• A control arm. The randomised designs in sarcopenia research provide comparison groups; the observational lung and oncology studies do not, by design (PMID 37096577).
• Pre-specified safety capture. The peptide therapies review highlighted safety and efficacy assessment as the central question for unapproved performance peptides (PMID 41966639).

How to read timeline claims found elsewhere

1. Check the species and system. Cell-culture differentiation work runs on days-to-weeks in a dish and was never intended as a human schedule (PMID 41236707).
2. Check whether the molecule matches. FSTL1 and FSTL3 findings belong to their own literatures (PMID 41996175, PMID 41296128).
3. Check whether anything was administered. A biomarker measured during a training programme reflects that programme (PMID 34201810).
4. Check the design label. Transcriptomic and cross-sectional analyses cannot generate timelines (PMID 40500689).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, laboratory testing, or investigational compound. Nothing here describes a protocol, and no outcome on any schedule should be inferred from the measurement windows summarised above.

References

• Effects of 16 Weeks of Resistance Training on Muscle Quality and Muscle Growth Factors in Older Adult Women with Sarcopenia: A Randomized Controlled Trial (International Journal of Environmental Research and Public Health, 2021)
• Effects of 12-week whole-body vibration training versus resistance training in older people with sarcopenia (Scientific Reports, 2025)
• Effectiveness of low-load resistance training with blood flow restriction vs. conventional high-intensity resistance training in older people diagnosed with sarcopenia: a randomized controlled trial (Scientific Reports, 2024)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Relative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments (Endocrine Reviews, 2024)
• Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension (Circulation, 2023)
• Activin A/Follistatin Axis in Airway Diseases and its Association With Recurrent Exacerbations (In Vivo, 2025)
• Transcriptomic analysis reveals shared deregulated neutrophil responses in COVID-19 and idiopathic pulmonary fibrosis (Respiratory Research, 2025)
• FSTL3 is a biomarker of poor prognosis and associated with immunotherapy resistance in ovarian cancer (Journal of Experimental & Clinical Cancer Research, 2025)
• FSTL3-Driven Cuproptosis Resistance and EPCs Promote OSCC Metastasis (Journal of Dental Research, 2026)
• FSTL1 is a prognostic marker and promotes invasion and metastasis of colon cancer (Discover Oncology, 2025)
• Derivation of Granulosa-Like Cells from Human Endometrial iPSCs for Autologous Estradiol Production (Tissue Engineering and Regenerative Medicine, 2025)